PAZOPANIB TEVA 400 mg, film-coated tablet 30 tablets
Active ingredients: Pazopanib hydrochloride, Pazopanib
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- PAZOPANIB TEVA 400 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- flacon(s) polyéthylène haute densité (PEHD) de 30 comprimé(s) avec fermeture de sécurité enfant
- Marketing authorisation holder
- TEVA SANTE
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 17 Dec 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Requires special monitoring during treatment
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63232033CIP73032706CIP133400930327067Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| PAZOPANIBcomprimé | 400 mg · un comprimé | FT |
| CHLORHYDRATE DE PAZOPANIBcomprimé | — | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.